Showing results (1-10 of 22) with videos related to
Sort By:
Pageof 3
Seminars in Interventional Radiology|June 4, 2015
Common complications of nonvascular percutaneous thoracic interventions: diagnosis and managementAzzam Khankan, Shireen Sirhan, Fadi ArisCancer|May 13, 2005
Red cell mass and plasma volume measurements in polycythemia: evaluation of performance and practical utilityShireen Sirhan, Virgil F Fairbanks, Ayalew TefferiHaematologica|March 8, 2005
Neutrophil polycythemia rubra vera-1 expression in classic and atypical myeloproliferative disorders and laboratory correlatesShireen Sirhan, Terra L Lasho, Michelle A Elliott, et al.American Journal of Blood Research|November 3, 2012
Emerging therapeutic options for myelofibrosis: a Canadian perspectiveVikas Gupta, Lynda Foltz, Shireen Sirhan, et al.British Journal of Haematology|December 21, 2004
Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patientsBrijesh Arora, Shireen Sirhan, James D Hoyer, et al.American Journal of Hematology|February 13, 2008
The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyureaShireen Sirhan, Terra L Lasho, Curtis A Hanson, et al.BMJ Supportive & Palliative Care|April 17, 2023
End of life in haematology: quality of life predictors - retrospective cohort studyVictoria Korsos, Alla'a Ali, Talia Malagon, et al.Blood|August 22, 2025
Artificial Intelligence in HematologyAziz Nazha, Olivier Elemento, Sanjay Ahuja, et al.JCO Oncology Practice|March 6, 2020
Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm GroupVikas Gupta, Sonia Cerquozzi, Lynda Foltz, et al.Haematologica|September 17, 2016
A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosisVikas Gupta, Ruben A Mesa, Michael W N Deininger, et al.Pageof 3